Marlex Pharmaceuticals Inc.

New Castle, DE Doing business as Marlex Pharmaceuticals I

UEI
VSSNJEFMPLB3
CAGE
1TAP7
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

FY2025 rankings
Self-certified in SAM.gov
  • For Profit Organization
  • Minority Owned Business
  • Subcontinent Asian (Asian-Indian) American Owned
  • Self Certified Small Disadvantaged Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
65 Lukens Dr, New Castle, DE 19720, USA
Website
marlexpharm.com
Founded
1992
Employees
1-10
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
51 Wholesale Trade – Nondurable Goods

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $109,115
FY2025 $34,134
FY2024 $39,691
FY2023 $31,231

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Defense Logistics Agency $109,115

Contract vehicles

Contract awards

Award Agency Obligated Awarded
Prednisone 20 MG tablet 100S SPE2D326F298L Medical Supply Chain (DLA) $299
Hydroxyzine HCL 25 MG tablet 100S SPE2D326F289D Medical Supply Chain (DLA) $15
Furosemide 40 MG tablet 100S SPE2D326F271L Medical Supply Chain (DLA) $29
Prednisone 20 MG tablet 100S SPE2D326F269J Medical Supply Chain (DLA) $39
Hydroxyzine HCL 25 MG tablet 100S SPE2D326F268B Medical Supply Chain (DLA) $7

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Marlex Pharmaceuticals Inc., doing business as Marlex Pharmaceuticals I, manufactures and supplies generic pharmaceutical tablets to federal healthcare systems as a prime contractor under full-and-open procurement, with no set-aside usage across its federal footprint. A minority-owned, Subcontinent Asian American-owned small disadvantaged business headquartered in New Castle, Delaware, Marlex holds 472 prime awards (100% of recent activity) with combined potential value of $404.6 million, driven by high-volume delivery orders placed through established federal medical supply channels.

Marlex's customer concentration anchors heavily to the Veterans Health Administration and the Defense Logistics Agency. The top five funding entities account for 93% of recent awards by count and 99% by potential value. The Defense Logistics Agency Troop Support Medical dominates by award frequency with 391 delivery orders (combined potential value $89.5 million), while the Department of Veterans Affairs Veterans Integrated Service Network 12 leads by dollar value with 11 awards carrying $240.4 million in combined potential value. The VA National Acquisition Center contributes an additional $68.1 million across seven awards. Activity has grown sharply—from six awards in 2022 to 99 awards in 2026—reflecting sustained demand across federal beneficiary agencies. The recompete cliff shows only one award (combined potential value $100 thousand) completing in the next twenty-four months, indicating stable contract positioning with minimal near-term recompete exposure.

Marlex's product portfolio consists of prednisone, haloperidol, methocarbamol, loratadine, cetirizine HCl, thiamine, pyrazinamide, alendronate, ezetimibe, ropinirole HCl, and melatonin tablets in multiple dosages and formulations. Representative delivery orders include a $100,232.91 firm fixed-price order from the DLA Troop Support Medical (awarded June 2026) for generic pharmaceutical tablets supporting federal healthcare systems, and numerous $3 to $800+ individual line-item delivery orders for specific medications such as prednisone 20 mg tablets (100s), methocarbamol 500 mg tablets (500s), and hydroxyzine HCl 25 mg tablets across the DLA supply chain. Marlex also holds three major parent contract vehicles: an IDC (SPE2D020D0008) with 259 task orders valued at $286 thousand combined, an IDC (SPM2D012D0005) with 130 task orders valued at $64 thousand combined, and a GSA Federal Supply Schedule contract (V797P5688X, Pharmaceuticals and Drugs) awarded February 1, 2025, with a ceiling of $204.8 million through February 1, 2030. Three single-award indefinite-delivery contracts with the VA National Acquisition Center round out the vehicle portfolio: a $5.9 million melatonin tablets and capsules IDC (base year September 2026 through September 2027, with four one-year options), a $4.3 million alendronate tablets IDC (base year May 2026 through May 2027, with four one-year options), and a $14.1 million ezetimibe 10 mg tablets IDC (base year April 2024 through April 2025, with four one-year options). Place of performance spans nationwide, with supplies distributed through VA pharmaceutical prime vendor programs and the DLA supply chain to serve the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service. Marlex operates exclusively as a prime contractor and does not subcontract work; all 472 awards reflect direct delivery of pharmaceutical products by the company.

Quick answers

Is Marlex Pharmaceuticals Inc. registered in SAM.gov?

Yes. Marlex Pharmaceuticals Inc.'s SAM.gov registration is active through September 3, 2027.

Which contract vehicles does Marlex Pharmaceuticals Inc. hold?

Marlex Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

How much has Marlex Pharmaceuticals Inc. received in federal contracts?

Federal contracts obligated $34,134 to Marlex Pharmaceuticals Inc. in fiscal year 2025 and $214,171 in fiscal years 2023 through 2027.

How does Marlex Pharmaceuticals Inc. rank among federal contractors?

Marlex Pharmaceuticals Inc. ranked #40 in NAICS 325411 in FY2025.

What is Marlex Pharmaceuticals Inc.'s most recent federal award?

Marlex Pharmaceuticals Inc.'s most recent federal contract award is Prednisone 20 MG tablet 100S (SPE2D326F298L), from Medical Supply Chain (DLA), on July 24, 2026.

On GovTribe

See Marlex Pharmaceuticals Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors